← Product Code [LDJ](/productcode/LDJ) · K963916 # IMMULITE CANNABINOIDS (K963916) _Diagnostic Products Corp. · LDJ · Apr 28, 1997 · Clinical Toxicology · SESE_ **Canonical URL:** https://fda-staging.innolitics.com/device/K963916 ## Device Facts - **Applicant:** Diagnostic Products Corp. - **Product Code:** [LDJ](/productcode/LDJ.md) - **Decision Date:** Apr 28, 1997 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 862.3870 - **Device Class:** Class 2 - **Review Panel:** Clinical Toxicology ## Indications for Use IMMULITE® Cannabinoids is a solid-phase, chemiluminescent enzyme immunoassay designed for use with the IMMULITE® Automated Analyzer for the semiquantitative and qualitative measurement for cannabinoids and metabolites in urine. It is intended strictly for in vitro diagnostic use in the context of a program involving an established confirmatory test for tetrahydrocannabinol (THC, cannabis, marijuana) and its metabolites. ## Device Story IMMULITE Cannabinoids is a solid-phase, chemiluminescent enzyme immunoassay for urine analysis. The device uses a polystyrene bead coated with monoclonal antibodies specific for cannabinoids. Patient urine and alkaline phosphatase-conjugated 11-nor-Δ⁹-tetrahydrocannabinol-9-carboxylic acid (THCA) are incubated with the bead; cannabinoids in the sample compete with enzyme-labeled THC for antibody binding sites. After a centrifugal wash, a phosphate ester of adamantyl dioxetane substrate is added. Alkaline phosphatase hydrolyzes the substrate, producing a sustained chemiluminescent light emission measured by a luminometer. Photon output is inversely proportional to cannabinoid concentration. The device is used in clinical laboratories with the IMMULITE Automated Analyzer. Results provide a preliminary analytical test, intended to be used alongside established confirmatory testing (e.g., GC/MS) to support clinical decisions regarding cannabinoid use or abuse. ## Clinical Evidence Method comparison study on 456 urine samples (range: nondetectable to >2500 ng/mL). Compared against Roche Abuscreen Online THC (99.2% relative sensitivity, 98.2% relative specificity) and Abbott AxSYM Cannabinoids (96.3% relative sensitivity, 99.0% relative specificity). Discrepancies were analyzed using GC/MS; discordant results were generally found to be nondetectable by GC/MS, confirming the device's performance is consistent with established immunoassays. ## Technological Characteristics Solid-phase chemiluminescent enzyme immunoassay. Components: polystyrene bead coated with monoclonal anti-cannabinoid antibodies, alkaline phosphatase-conjugated THCA, phosphate ester of adamantyl dioxetane substrate. Form factor: Test Unit for use with IMMULITE Automated Analyzer. Detection: luminometer measuring light emission. Connectivity: automated analyzer system. ## Regulatory Identification A cannabinoid test system is a device intended to measure any of the cannabinoids, hallucinogenic compounds endogenous to marihuana, in serum, plasma, saliva, and urine. Cannabinoid compounds include delta-9-tetrahydrocannabinol, cannabidiol, cannabinol, and cannabichromene. Measurements obtained by this device are used in the diagnosis and treatment of cannabinoid use or abuse and in monitoring levels of cannabinoids during clinical investigational use. ## Special Controls *Classification.* Class II (special controls). A cannabinoid test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military). ## Predicate Devices - Roche Abuscreen Online THC ([K961620](/device/K961620.md)) - Abbott AxSYM Cannabinoids ([K951288](/device/K951288.md)) - DPC's Third Generation TSH Control Module ([K930007](/device/K930007.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} Diagnostic Products Corporation 5700 West 96th Street Los Angeles, CA 90045 Tel: (213) 776-0180 Fax: (213) 776-0204 K963916 APR 28 1997 # 510 (k) Summary of Safety and Effectiveness This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR Part 807.92. **Name:** Diagnostic Products Corporation (DPC) **Address:** 5700 West 96th Street Los Angeles, CA 90045-5597 **Telephone Number:** (213) 776-0180 **Facsimile Number:** (213) 776-0204 **Contact Person:** Edward M. Levine, Ph.D. Director of Clinical Affairs **Date of Preparation:** April 3, 1997 **Device Name:** **Trade:** IMMULITE® Cannabinoids **Catalog #:** LKTH1 (100 tests), LKTH5 (500 tests) **Common:** Reagent system designed as a semiquantitative measurement for cannabinoids in urine. **CFR:** A device intended to measure any of the cannabinoids, hallucinogenic compounds endogenous to marijuana, in serum, plasma, saliva, and urine. Cannabinoid compounds include delta-9-tetrahydrocannabinol, cannabidiol, cannabinol, and cannbichromene. Measurements obtained by this device are used in the diagnosis and treatment of cannabinoid use or abuse and in monitoring levels of cannabinoids during clinical investigational use. **Classification:** Class II device (21 CFR 862.3870), 91-LDJ **Panel:** Toxicology **Accessory Trade:** IMMULITE® Cannabinoids Control Module **Common:** Quality Control Material (assayed & unassayed) **CFR:** A device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. **Classification:** Class I device (21 CFR 862.1660), 82-JJX **Panel:** Immunology {1} Diagnostic Products Corporation 5700 West 96th Street Los Angeles, CA 90045 Tel: (213) 776-0180 Fax: (213) 776-0204 # DPC **Manufacturer:** Diagnostic Products Corporation (DPC) 5700 West 96th Street Los Angeles, CA 90045-5597 **Establishment Registration #:** DPC: 2017183 **Substantial Equivalent Predicate Device:** Roche Abuscreen Online THC (K961620) Abbott AxSYM Cannabinoids (K951288) and DPC's Third Generation TSH Control Module (K930007) ## Description and Intended Use of Device: IMMULITE® Cannabinoids is a solid-phase, chemiluminescent enzyme immunoassay designed for use with the IMMULITE® Automated Analyzer for the semiquantitative and qualitative measurement for cannabinoids and metabolites in urine. It is intended strictly for *in vitro* diagnostic use in the context of a program involving an established confirmatory test for tetrahydrocannabinol (THC, cannabis, marijuana) and its metabolites. ## Substantial Equivalence Claim: Diagnostic Products Corporation (DPC) asserts that DPC's IMMULITE® Cannabinoids is substantially equivalent to Roche Abuscreen Online THC and Abbott AxSYM Cannabinoids assays. ## Intended Use Equivalence: The IMMULITE Cannabinoids assay is designed for the semiquantitative and qualitative measurement of cannabinoids in urine. Abuscreen Online THC is an in vitro diagnostic test for the qualitative and semiquantitative detection of cannabinoids in human urine and the AxSYM Cannabinoids assay is a semiquantitative reagent system for the detection of cannabinoids in human urine. Each product is intended strictly for *in vitro* diagnostic use, and each product provides a preliminary analytical test result. {2} Diagnostic Products Corporation 5700 West 96th Street Los Angeles, CA 90045 Tel: (213) 776-0180 Fax: (213) 776-0204 # DPC® ## Technological Comparison to Predicate: The IMMULITE® Cannabinoids is a chemiluminescent immunoassay. The technology of the IMMULITE® Cannabinoids assay is identical to the technology used in previously cleared and commercially marketed IMMULITE® products. IMMULITE® Cannabinoids is a solid-phase, chemiluminescent immunoassay. The solid phase, a polystyrene bead enclosed within an IMMULITE® Test Unit, is coated with a monoclonal antibody specific for cannabinoids. The patient sample and alkaline phosphatase-conjugated 11-nor-Δ⁹-tetrahydrocannabinol-9-carboxylic acid (THCA) are simultaneously introduced into the Test Unit, and incubated for 30 minutes at 37°C with intermittent agitation. During this time, cannabinoids in the sample compete with the enzyme-labeled THC for a limited number of antibody binding sites on the bead. Unbound enzyme conjugate is then removed by a centrifugal wash, after which substrate is added and the Test Unit is incubated for a further 10 minutes. The chemiluminescent substrate, a phosphate ester of adamantyl dioxetane, undergoes hydrolysis in the presence of alkaline phosphatase to yield an unstable intermediate. The continuous production of this intermediate results in a sustained emission of light, thus improving precision by providing a window for multiple readings. The bound complex - and thus also the photon output as measured by the luminometer - is inversely proportional to the concentration of cannabinoids in the sample. **Abuscreen Online** Automated Assays are based on the kinetic interaction of microparticles in a solution (KIMS) as measured by changes in light transmission. In the absence of sample drug, free antibody binds to drug-microparticle conjugates, causing the formation of particle aggregates. When a urine sample containing the drug in question is present, this drug competes with the particle-bound drug derivative for free antibody. Antibody bound to sample drug is no longer available to promote particle aggregation, and subsequent particle lattice formation is inhibited. As the aggregation reaction proceeds in the absence of sample drug, the absorbance change increases. Conversely, the presence of sample drug diminishes the increasing absorbance in proportion to the concentration of drug in the sample. Sample drug content is determined relative to the value obtained for a known cutoff concentration of drug. The AxSYM Cannabinoids assay utilizes fluorescence Polarization Immunoassay (FPIA) technology. In the FPIA reaction process, specimen analyte and analyte-tracer compete for binding sites on antibodies. If the specimen contains a high concentration of the analyte, then specimen analyte binds to the antibodies, leaving the analyte-tracer unbound. If the specimen contains a low concentration (or no concentration) of the analyte, then few or no analyte molecules bind to the antibodies, leaving the antibodies open for the analyte-tracer to bind. FPIA optics measure the change in polarized light to determine the concentration of unbound analyte-tracers, and therefore the concentration of analytes in the specimen (fluorescence polarization). {3} Diagnostic Products Corporation 5700 West 96th Street Los Angeles, CA 90045 Tel: (213) 776-0180 Fax: (213) 776-0204 # DPC ## Performance Equivalence - Method Comparison The IMMULITE Cannabinoids procedure was compared to two commercially available immunoassays for cannabinoids, Roche Abuscreen OnLine THC and Abbott AxSYM Cannabinoids Assay on a total of 456 urine samples with a range from nondetectable to over 2500 ng/mL. Randomly selected drug-free and drug-containing urine samples were obtained from a Hospital in Switzerland, and tested on site. The results of the comparisons are presented in the tables below. | Roche Abuscreen Online | IMMULITE Cannabinoids | | Relative Sensitivity | Relative Specificity | | --- | --- | --- | --- | --- | | | Pos. | Neg. | | | | | 235 | 2 | 99.2% | 98.2% | | | 4 | 215 | | | The two cases where IMMULITE results were negative and Roche results were positive were both found nondetectable by the GC/MS procedure. The GC/MS values for the four cases where IMMULITE results were positive and Roche results were negative ranged from nondetectable to 80 ng/mL. | Abbott AxSYM Pos. | IMMULITE Cannabinoids | | Relative Sensitivity | Relative Specificity | | --- | --- | --- | --- | --- | | | Pos. | Neg. | | | | | 237 | 9 | 96.3% | 99.0% | | Neg. | 2 | 208 | | | The nine cases where IMMULITE results were negative and Abbott AxSYM results were positive were all found nondetectable by the GC/MS procedure. The two cases where IMMULITE results were positive and Abbott AxSYM results were negative were both 18 ng/mL in the GC/MS procedure. {4} Diagnostic Products Corporation 5700 West 96th Street Los Angeles, CA 90045 Tel: (213) 776-0180 Fax: (213) 776-0204 DPC # Substantial Equivalence Claim for the IMMULITE Cannabinoids Control Module Diagnostic Products Corporation (DPC) asserts that the IMMULITE Cannabinoids Control Module, which is sold separately from the IMMULITE Cannabinoids kit, is substantially equivalent to other commercially available assayed controls, such as DPC's Third Generation TSH Control Module (K930007). ## Intended Use Equivalence: Each product is designed for monitoring day-to-day performance of a particular assay. Each product is intended strictly for in vitro diagnostic use, and is supplied lyophilized, requiring reconstitution. The controls are intended to be assayed as an unknown, in the same manner as a patient sample, in the context of an internal quality control program. ## Clinical Studies: Not applicable ## Conclusion: The conclusions drawn from the nonclinical tests demonstrate that the device is safe, effective, and performs as well as or better than the legally marketed device. ![img-0.jpeg](img-0.jpeg) Edward M. Levine, Ph.D. Director of Clinical Affairs ![img-1.jpeg](img-1.jpeg) --- **Source:** [https://fda-staging.innolitics.com/device/K963916](https://fda-staging.innolitics.com/device/K963916) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com